SecBot SecBot
25-NSE ·Filed Apr 8, 2026

AZN

ASTRAZENECA PLC
NEUTRAL
Impact 2/10
Horizonimmediate Processed7mo ago SEC0000876661-26-000343
Notable filing: 25-NSE
Actionable Insight • Neutral

No trading or investment action is required; this is a standard post-maturity administrative step. Investors should note that AstraZeneca has fulfilled its obligation on this debt issue, reducing future interest expense.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$204.16
T+0 close · Apr 8, 2026 · via day close
Latest settled
−4.41%
T+60 · $195.15
Vs SPY
−14.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 8 $204.16entry
  2. T+1 · 7mo ago +0.37%α −0.21% · $204.91
  3. T+5 · 7mo ago −1.55%α −5.06% · $201.00
  4. T+20 · 7mo ago −11.23%α −19.77% · $181.24
  5. T+60 · 4mo ago −4.41%α −14.58% · $195.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca PLC's 0.700% Notes due 2026 were redeemed at maturity on April 8, 2026, prompting the New York Stock Exchange to notify the SEC of the removal of the related securities from listing and registration. This is a routine administrative action following the maturity of debt obligations.

Key Facts

  • The 0.700% Notes due 2026 were redeemed at maturity on April 8, 2026.
  • NYSE filed Form 25-NSE to remove the guarantor of these notes from listing and registration.
  • Trading in the security was suspended on April 8, 2026.
  • This action is pursuant to SEC Rule 12d2-2(a)(2), which allows for delisting of matured or retired securities.

Financial Impact

Redemption of notes at maturity, no additional financial impact beyond normal debt repayment.

debtinterest expense

Risk Factors

  • None material, this is a routine redemption of matured debt.
  • Minimal operational risk as the delisting follows contractual maturity.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0000876661-26-000343
Document: 0000876661-26-000343-index.html0000876661-26-000343
Document: 0000876661-26-000343.txt0000876661-26-000343

Track record

77 reports on AZN

Performance horizon

19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026